W
WellDoc
Digital health company revolutionizing chronic disease management
About WellDoc
Welldoc operates in the digital health sector, focusing on chronic care management through its flagship product, BlueStar. BlueStar is an FDA-cleared Software as a Medical Device (SaMD) designed to manage type 1 and type 2 diabetes. The platform leverages scientific rigor and real-world studies to provide personalized health activation and support adherence to treatment plans. Welldoc collaborates with various partners, including Dexcom and Redox, to enhance its offerings and optimize provider interactions. The company serves a diverse client base, including employers, health plans, health systems, and individual users. Its business model revolves around providing digital health solutions that are reimbursed by CMS for remote patient monitoring. Welldoc generates revenue through subscriptions and partnerships, aiming to empower individuals to take control of their health through precise and personalized care strategies.
Source: Dealroom company dataAt a glance
- Founded
- 2005
- Headquarters
- Columbia, United States
- Sector
- Health Tech & Medtech
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Windham Venture Partners- TCTCP Venture Capital
Merck Global Health Innovation Fund
Samsung Ventures
Adage Capital
Excel Venture Management
Asset Management Ventures
Hudson River Capital Partners
Alexandria Venture Investments
Johnson & Johnson Innovation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about WellDoc on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See WellDoc on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.